Develops cell therapies for disc and spine conditions and metabolic disorders.
Mar 2026Revenue $358K/yrExpenses $14.6M/yr
No trendCash runway ≈ 4 months from Mar 2026
Figures by year
When will BioRestorative Therapies be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Mar 2026, revenue was $358K and expenses $14.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $360K | $16.0M | −$15.6M |
| Dec 2024 | $401K | $12.0M | −$11.6M |
| Dec 2023 | $146K | $15.4M | −$15.2M |
| Dec 2022 | $120K | $19.1M | −$19.0M |
| Dec 2021 | $46.0K | $26.4M | −$26.3M |
| Dec 2020 | $77.0K | $2.83M | −$2.75M |
| Dec 2019 | $130K | $8.56M | −$8.43M |
| Dec 2018 | $111K | $7.76M | −$7.65M |
| Dec 2017 | $81.0K | $8.46M | −$8.37M |
| Dec 2016 | $36.4K | $7.82M | −$7.79M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.